2024 ARCHIVES

OVERVIEW
DOWNLOAD BROCHURE
KEYNOTES
USER GROUPS
ATTENDEES
ATTENDEES PROFILE
PARTNERING ORGANIZATIONS
Trial Design and Protocol Development banner

Drug development organizations understand the need to include patient and site perspectives in protocol design and planning. Incorporating patient voice, as well as site perspectives into clinical trial design and protocol development leads to better recruitment, retention, satisfaction, and to increased likelihood of trial success. The Trial Design and Protocol Development conference evaluates new strategies to improve and optimize protocol design, methods to incorporate participant voice, and collaborative approaches to reduce site and patient burden.

Monday, 28 October

MONDAY AFTERNOON: USER GROUP & WORKSHOP

14:30– 19:00 Innovation Day with IQVIA Technologies at SCOPE Europe

CO-SPEAKERS:​

Garth Dabbs, Vice President, Product Strategy, DPS, IQVIA

Stefan Dürr, Senior Director, Client Delivery, IQVIA Technologies

Petar Genov, Senior Director, Business Operations and Capabilities – Payments, IQVIA Technologies

Raphaelle Gilg, SSO Strategy & Operations Manager, Novartis

Bernhard Glombitza, Vice President & Head of Clinical Operations and Customer Engagement EMEA & LATAM, Bayer 

Bernd Haas, Senior Vice President, Digital Products & Solutions, IQVIA

Adrian Kizewski, Associate Director, Clinical Technology, IQVIA Technologies

Kevin Landells, Vice President Patient Centered Technology Delivery, IQVIA Technologies

Alison Liddy, Senior Vice President, Patient and Site Centric Solutions, IQVIA

Marisa Minetti, Patient Research Partner, Chiesi Group

Majd Mirza, PhD, Chief Innovation Officer, Viedoc

Chloe Rose, Executive Director, Portfolio Management, Pratia​

Clinical trial sponsors are invited to join IQVIA Technologies’ digital product leaders and clinical trial sponsor executives for an afternoon of discussions, demos, and networking. IQVIA will share our vision to transform clinical operations, demonstrate our technologies that improve the patient, site, and sponsor journeys, and ask for your input on our roadmap for future product development. A highlight of the agenda is the industry panel discussion on the latest research and trends in clinical technology and its impact on productivity. Innovation Day is complimentary and will be of interest to pharmaceutical executives or sites with roles in clinical operations, innovation, technology, finance, budgeting, data analytics, patient or site engagement, or strategic sourcing. IQVIA reserves the right to decline registrations for those not in these categories. For more information or to register click here.​
17:30– 19:00 The Path towards Sustainable Clinical Trials: How to Minimise Environmental Impact and Stay Ahead of Future Regulatory Requirements

INSTRUCTORS:
Fiona Adshead, Chair, Sustainable Healthcare Coalition
Thierry Escudier, Portfolio Lead, Pistoia Alliance
Marisa Minetti, Patient Research Partner, Chiesi Group
Keith Moore, Programme Coordinator, Sustainable Healthcare Coalition
Developing frameworks to define and manage sustainability risks, and effective guidelines to reduce the carbon footprint of clinical trial operations is a collaborative effort. Beyond benefiting the environment, adopting sustainable practices is increasingly demanded by stakeholders and can significantly influence customer choices and talent acquisition. Perhaps more compelling are the growing regulatory pressures and expectations, including the Corporate Sustainability Reporting Directive (CSRD) and Task Force on Climate-related Financial Disclosures (TCFD) among others. This workshop will discuss the current hotspots of carbon emissions in clinical research, introduce a new clinical trial carbon footprint calculator for assessing current state, and suggest introductory reduction strategies. Whether you are in clinical trial design clin ops, procurement, innovation, sustainability, or resource management, this workshop is for you.

Tuesday, 29 October

SCOPE Europe Fun Run/Walk Up the Magic Fountain Steps07:00

Join SCOPE Europe’s Coordinators for our Fun Run/Walk! All of us at Cambridge Healthtech Institute recognise the importance of integrating well-being and fitness into our work travel routines. This is an easygoing, informal running (or walking) event where we ascend the stairs of the iconic Magic Fountain. No time chips, running bibs, or energy bars—just a laid-back opportunity for a small group to start the day on a positive note. You can sprint, run, jog, walk, jog-and-talk, or walk-and-talk—the goal is to get up and get moving! Meet us in the front lobby at the InterContinental at 7 sharp!

Registration and Morning Coffee07:45

Organiser's Welcome Remarks08:50

INTEGRATING PATIENT VOICE IN EARLY-STAGE DEVELOPMENT

08:55

Chairperson's Remarks

Léa Proulx, Patient Voice Partner, Strategy, Portfolio & Operations, Roche

09:00

Unleashing Valuable Patient Insights: The Transformative Power of Patient Perspective in Operationalising Decentralised Clinical Trials

Marisa Minetti, Patient Research Partner, Chiesi Group

Ylenia Paleari, PhD, Patient Engagement Manager, Global Rare Diseases R&D Clinical Development, Chiesi Group

How insights from collaborative studies with patients and health care professionals in the USA and Europe, revealing perspectives on the benefits and challenges of DCTs, can help shape the future of patient-centric research in advancing DCTs in respiratory and rare diseases. This session discusses the implications of these results and explores actionable insights on modifying DCTs to better address the needs and preferences of both patients and HCPs.

09:25

Integrating Patient Perspective in Early-Stage Development: Actions Outweigh Words

Dominik Kraus, PhD, Principal Clinical Scientist, Roche

Léa Proulx, Patient Voice Partner, Strategy, Portfolio & Operations, Roche

Integrating patient insights into early protocol development is paramount in making key patient-inclusive development decisions in determining target patient population, endpoint selection, eligibility criteria, and schedule of assessment. Roche will share their approach to assess a patient-inclusive mindset, addressing gaps from both strategic and tactical perspectives and providing concrete examples on how to integrate patient insights in an early, systematic, and timely manner to design and implement patient-inclusive trials.

09:50

Assumptions Are the Root of Mistakes: Designing Studies Whilst Avoiding ‘Unicorn’ Protocols

Melissa Harris, Global Head, Patient Recruitment & Engagement, Fortrea

Assumptions in trial design impacts everything. Headways been made with patient-centric design philosophy but ultimately its sites who must execute the study. Listening to and incorporating input from sites and patients concurrently drives new treatments to the right patients, faster. A duel-centric approach is a potent model for achieving efficiency whilst meeting demands of sponsors and patients, beyond simply listening for intelligent, and compassionate protocol measures.

10:15

Overcoming Access Barriers for the Sexual and Gender Minority (SGM) Community: Actionable Measures from Protocol Design through Recruitment & Retention

Terttu Haring, MD, President, Site & Patients, Global Clinical Operations, Syneos Health

Garo Kiledjian, Founder & CEO, SGM Alliance

Kamil Kuhr, Director of R&D GxP Learning Operations, AstraZeneca

Binita Patel, MSc, Diversity Strategy Lead, Bayer

Join us for a thought-provoking session as we kick off with an introduction to SGM Alliance, an organization paving the way in addressing health inequities faced by the SGM community, often overlooked in clinical research. Hear from sponsors who have collaborated with SGM Alliance and experienced the positive impact of their partnership. Each speaker will share their experiences with SGM Alliance’s initiatives as we delve into innovative strategies to achieve inclusive clinical research that supports SGM populations. Explore how to address systemic barriers in clinical research through inclusive language, expanded demographic data collection, and culturally responsive education for clinical site staff and healthcare providers (HCP). Learn actionable measures to include SGM in clinical study design, spanning from protocol design through recruitment and retention. Together, let’s bridge the gaps and drive meaningful change for a more inclusive and accessible landscape in clinical research.

10:40

Embracing a Patient-First Approach in Clinical Trial Design: Leveraging Granular Data for Precision Planning

Elke Ydens, Assoc Dir Business Solutions, Data, Anju Software

With trials increasingly targeting more specific patient sub-populations, identifying and incorporating granular, high-quality, historical datasets is crucial to match expectation and reality in trial design and planning. This presentation addresses the complexities of sourcing and utilizing patient subset data while showcasing how our new strategic feasibility application is revolutionizing the process by delivering more precise, data-driven insights that will keep improving trial planning.

Grand Opening Coffee Break in the Exhibit Hall10:53

The SCOPE Europe Exhibit Hall is the best place to fuel up with a mid-morning coffee while visiting with our many exhibitors. Learn about what’s new in the industry, connect with colleagues and vendors, and make some new friends.

TUESDAY MORNING PLENARY SESSION:
REINVENTING CLINICAL DEVELOPMENT & CONVERGING RESEARCH WITH CLINICAL CARE

11:50

Chairperson's Remarks

Micah Lieberman, Executive Director, Cambridge Healthtech Institute; Co-Founder, ClinEco

11:55 KEYNOTE PRESENTATION:

Reinventing Clinical Development and Overcoming Unnecessary Complexity

Bernhard Glombitza, Head, Clinical Operations EMEA and LATAM, Bayer

This keynote presentation proposes a paradigm shift in clinical development, advocating for the adoption of a minimal viable product (MVP) approach focused solely on fulfilling regulatory requirements. By streamlining processes and resources to the essentials, this strategy promises significant cost reductions and time efficiencies while maintaining regulatory compliance. Through case studies and implementation strategies, attendees will gain insights into how embracing this innovative approach can revolutionise clinical development, paving the way for greater agility, adaptability, and patient-centricity in the industry.

12:20 KEYNOTE PRESENTATION:

ClinEco Commons and the Power of the Clinical Research Community

Micah Lieberman, Executive Director, Cambridge Healthtech Institute; Co-Founder, ClinEco

The Commons is a ClinEco and SCOPE resource. It is a go-to hub for resources, tools, news, regulatory updates, and more, designed to support professionals in the field of clinical research. The Commons serves as a collaborative space where you can access, visit, share valuable content as well as contribute to the wealth of knowledge within the SCOPE and ClinEco community. The "Ask a ClinEco Luminary" feature allows users to connect directly with research leaders to learn from colleagues.

12:30 KEYNOTE PANEL DISCUSSION:

Converging Clinical Research with Clinical Care: A Multi-Stakeholder Panel on Tackling This Bold Vision

PANEL MODERATOR:

Paul Duffy, Head, Global Clinical Site Partnerships, MSD

This plenary panel will show how stakeholders across biopharma R&D have come together to develop pragmatic solutions that are foundational to enabling the future of drug development and integrating clinical research as part of the care continuum. This panel will feature biopharma industry leaders, Health Authorities, patient advocates, and other industry consortia candidly discussing why everyone must work together to drive innovation in the R&D ecosystem, shape the future of healthcare, and bridge the gap between clinical research and clinical care.

PANELISTS:

Maria Dutarte, Executive Director, European Patients’ Academy on Therapeutic Innovation (EUPATI)

Maria Koutsopoulou, Senior Vice President, Head of Global Development Operations, Merck KGaA

Bari Kowal, Senior Vice President & Head, Development Operations & Portfolio Management, Global Development, Regeneron Pharmaceuticals, Inc.

12:55

SCOPE Europe 2023 Accelerator Project Update and Outcomes: Innovative Outsourcing Process for Biotech

Micah Lieberman, Executive Director, Cambridge Healthtech Institute; Co-Founder, ClinEco

Last year at SCOPE Europe we engaged with sponsor orgs in attendance on a project with ClinEco, our B2B clinical research marketplace and network, to help with scoping, selection, and onboarding of outsourcing partners for a trial. The goal was to challenge the norms of clinical trials outsourcing, improve vendor selection, and speed up the RFI process...and more. We learned a lot with our partner and some of those key learnings apply to us all.

13:00 KEYNOTE PANEL DISCUSSION:

Quantifying the Collection of Non-Core and Extraneous Core Protocol Data and its Relationship with Clinical Trial Performance

PANEL MODERATOR:

Emily Botto, Senior Research Analyst, Tufts Center for the Study of Drug Development

This panel discussion provides perspectives and updates on a collaborative research study looking at optimizing non-core and extraneous clinical research data collection practices, with the aim to reduce patient and site burden. The panel will explore considerations that helped define the study methodology and insights expected from the study findings that will inform new protocol design strategies.

PANELISTS:

Paul Duffy, Head, Global Clinical Site Partnerships, MSD

Joachim Lovin, DCT Specialist, Novo Nordisk

13:25Transition to Networking Luncheon in the Exhibit Hall

Join Your Peers for a Networking Lunch in the Exhibit Hall13:35

Take this opportunity to refresh and refuel with our Exhibit Hall lunch. Enjoy good food and even better conversation during our walk and talk luncheon.

EVOLVING DCT APPROACHES: INNOVATION IN TRIAL DESIGN AND OPERATIONS

14:35

Chairperson's Remarks

Matthew Bonam, Vice President Digital Health, Evinova and AstraZeneca Company

14:40

Sponsor Experience Implementing Decentralised Clinical Trial (DCT) Elements: DCT Implementation Survey Results & Lessons Learned

Joachim Lovin, DCT Specialist, Novo Nordisk

To understand the current state and future direction of decentralized clinical trials post-COVID-19, a survey was conducted across 14 sponsor companies to assess implementation experiences, success factors, and challenges in global clinical trials.  Based on the survey learnings, this presentation will provide a greater understanding of innovative modern solutions that could help support more effective patient engagement and choice; A deeper understanding of best practices and barriers experienced when implementing DCT elements as part of global trials; A broad perspective of learnings related to DCT elements, across various stakeholders, that can be used to inform the ways of working for the industry and regulators; and access to available tools to support the acceleration of patient-centric modern approaches in clinical development.

15:05

Securing Patient Safety and Enhancing Clinical and Medical Operations in Hybrid and Decentralized Trial Designs

AJ Mills, Global VP Commercial, Veristat

Hugo Bernard, PhD, Mcs Medical Affairs Specialist, Medical Affairs, Veristat

15:30

Inconvenient Truths of Decentralised Clinical Trials (DCT)

Reamonn Madden, Innovation Capability Director, Global Clinical Operations Innovation, Novartis Pharmaceuticals

The experiences of COVID-19 restrictions and a return to a "new normal" permit a fairer perspective on opportunities and realities for decentralized clinical trials. This talk will provide reflections on the challenges for DCT implementation and what these mean for its use in the near future.

15:55

Bringing Clinical Trials to Everyone's Backyard through Community & Hybrid Trial Design

Stuart Redding, CEO, Medical Research Network Ltd

The industry historically fails to complete trials on time, as they are built around data and sites. Community and hybrid trial designs build the trial around the patient—opening up sites in new locations & offering treatment in the community or at home, giving access to diverse populations and providing the patients choice and control. This truly patient focused approach has proven to reduce trial challenges and maximize the return on investment by speeding up patient recruitment, increasing throughput per site and maintaining patient retention.

16:07 Unlocking the Power of Decentralised Clinical Trial (DCT): Navigating Trial Design Considerations in Modern Models

Ali Wherry, Director, Clinical Operations, Science37

Explore the future of clinical research through a new lens on Decentralized Clinical Trial (DCT) components. Often overlooked, the full potential of DCTs can be unlocked by prioritizing intentional planning from the outset. Join this session to discuss innovative trial design considerations that enhance operational feasibility and ease patient burden. Get set for a journey towards more efficient, patient-centric clinical trials!

16:32

Enhancing Patient Engagement and Satisfaction: Are Decentralised Trials Delivering on This Promise?

Stefania Collamati, DCT Operations Manager, Clinical Operations, Bayer SPA

Bayer has successfully implemented innovative trial designs that aim to fit the lifestyle of patients in both hybrid and fully decentralized clinical trials. With this presentation we take a deep dive into the DCT strategies Bayer has adopted and their impact on patient satisfaction, experience, and willingness to participate in future clinical trials which are offering more modern and flexible approaches.

Reception in the Exhibit Hall with Beer, Wine, and Tapas16:57

Wind down at the end of a busy session day with colleagues, beer, wine, and tapas. Have a drink with your favorite exhibitor and take a chance at winning a fabulous raffle prize (must be present to win)!

Close of Day18:00

Wednesday, 30 October

Registration and Morning Coffee08:15

NEW TRENDS IN PROTOCOL DESIGN: REDUCING SITE AND PATIENT BURDEN

08:45

Chairperson's Remarks

Marina Malikova, PhD, Executive Director, Surgical Translational Research, Operations and Compliance, Boston University School of Medicine

08:50

The Benefits of Building the Use of Digital Technologies into Clinical Program Design by First Intent

Matthew Bonam, Vice President Digital Health, Evinova and AstraZeneca Company

Digital technologies have the potential to accelerate the clinical development of new medicines and improve the patient and site experience of participating in a trial. If applied poorly, these same technologies can have the opposite effect. Case studies and patient testimonials will be used to describe the benefits of using digital technologies in clinical programs. Actionable insights will aid clinical teams in the design of digital-first clinical development programs.

09:15

Integrated Trail Optimization: An Innovative Approach to Study Design Including Both the Patient and Site Voices

Jenna McDonnell, Sr. Director Strategy & Innovation, PPD Clinical Research , Thermo Fisher Scientific

Caitlin Thomas, Research Scientist, PPD Clinical Research , Thermo Fisher Scientific

There are often challenges when designing clinical trials with tension between scientific and operational considerations, patient burden and site burden. The PPD clinical research business of Thermo Fisher Scientific offers Integrated Trial Optimization solutions that have been built to overcome these obstacles. Join us to learn how we use proprietary tools, data sources and capabilities together to deliver the optimal plan for program delivery, regulatory success and market access.

09:40

Optimisation of Protocol Design: A Path To Efficient, Lower Cost Clinical Trial Execution

Marina Malikova, PhD, Executive Director, Surgical Translational Research, Operations and Compliance, Boston University School of Medicine

This session will explore the challenges clinical teams face in developing protocols to ensure that the right patients are enrolled and the right data are collected to demonstrate that a drug is safe and efficacious, while managing study costs and study complexity based on proposed comprehensive scoring model. Key factors to consider when developing protocols and techniques to minimise complexity, as well as patient burden index, will be discussed. A methodology to identify processes at planning phase, approaches to increase fiscal return and mitigate fiscal compliance risk for clinical trials will be addressed.

Coffee Break in the Exhibit Hall10:17

More coffee, more exhibitors, more networking, and some delicious snacks. What’s not to love?

WEDNESDAY MORNING PLENARY SESSION:
INTEGRATING DIGITAL HEALTH TECH IN TRIALS & IMPROVING STUDY DESIGN WITH PATIENTS

11:00

Organiser's Welcome Remarks

Micah Lieberman, Executive Director, Cambridge Healthtech Institute; Co-Founder, ClinEco

11:05 KEYNOTE PRESENTATION:

From Documents to Data: Let’s Digitally Transform Our Clinical Trial Protocol

Frank Berger, MD, Expert Data & Analytics Solutions, Clinical Development & Operations, Boehringer Ingelheim

A massive, fundamental change is knocking on the door: the shift from a document-based to a data-based, machine-readable Clinical Trial Protocol. This talk shares some insights for exploring this new territory, including pitfalls and the need for a cross-functional approach.

11:20 KEYNOTE PANEL DISCUSSION:

Integrating Digital Health Technologies in Clinical Trials: A New Era for eCOA and ePRO

PANEL MODERATOR:

Moe Alsumidaie, Chief Editor, Editorials, Clinical Trial Vanguard

This panel will delve into how emerging digital health technologies, including eCOA and ePRO, are transforming patient data collection in clinical trials. It will cover the evolution of digital endpoints, patient-centric approaches, and the integration of these technologies into clinical research frameworks. How are digital health technologies, especially eCOA and ePRO solutions, revolutionizing data collection in clinical trials? Have they led to more patient-centric trials? What are the challenges in integrating these technologies into existing clinical trial frameworks, and how have they been overcome? What considerations should be made when selecting technology partners? Looking towards the future, how do you see digital health technologies evolving, and what implications will this have on clinical research?

PANELISTS:

Jacqueline Bowman, Co-Founder, Foundation for the Rights of Citizens with Obesity

Bernhard Glombitza, Head, Clinical Operations EMEA and LATAM, Bayer

Kai Langel, CEO, DEEP Measures

11:45 KEYNOTE PANEL DISCUSSION:

How to Build Meaningful Relationships and Shift to Patient-Led Conversations for Improved Study Design and Execution

PANEL MODERATOR:

Maria Dutarte, Executive Director, European Patients’ Academy on Therapeutic Innovation (EUPATI)

Join us for a critical exploration into the transformative approach of integrating patient insights into clinical trial protocols. This panel will explore how strong relationships and patient-led conversations can improve study design and execution, significantly easing the burden on sites and patients. Learn from experts about common pitfalls and challenges in patient engagement, gaining actionable strategies towards more effective and empathetic trials.

PANELISTS:

Jose Aibar, President, Dravet Syndrome Foundation Spain

Jacqueline Cannon, Chief Executive, The Lewy Body Society

Roger Legtenberg, PhD, Co-Founder, Partners4Patients Foundation UG

Join Your Peers for a Networking Luncheon in the Exhibit Hall12:10

Join us again for lunch in the Exhibit Hall. Last chance to visit with exhibitors you missed and to enter our final raffle!

ENGAGING PATIENTS AND SITES FOR BETTER TRIAL DESIGN

13:10 Chairperson's Remarks

Robert Loll, Senior Vice President, Business Development & Strategic Planning, Praxis

13:15

Protocol Design Trends—Opportunities to Lower Site and Patient Burden and Optimise Trial Execution

Emily Botto, Senior Research Analyst, Tufts Center for the Study of Drug Development

Zachary Smith, Senior Data Scientist, Tufts Center for the Study of Drug Development

Tufts CSDD has developed assessments for the burden experienced by both participants and trial sites when participating in clinical trials. These assessments (and other similar assessments) can identify sources of elevated burden and be used to identify ways to reduce the burden of participation and improve trial performance. They also highlight similarities and differences in the sources of burden experienced by trial participants and sites.

13:40 PANEL DISCUSSION:

Innovative Design Strategies to Reduce Trial Burden

PANEL MODERATOR:

Emily Botto, Senior Research Analyst, Tufts Center for the Study of Drug Development

PANELISTS:

FIRESIDE CHAT: Innnovative Protocol Design Strategies to Reduce Trial Burden

Firas Abdessalem, Head of GPV Signal, Risk & Oversight Digital Service Line, Sanofi

Frank Berger, MD, Expert Data & Analytics Solutions, Clinical Development & Operations, Boehringer Ingelheim

Alexandra Charge, CEO, ISPEP and Founder, reCharge reSearch Ltd

Zachary Smith, Senior Data Scientist, Tufts Center for the Study of Drug Development

Session Break14:30

WEDNESDAY AFTERNOON PLENARY SESSION:
NEW ERA OF RISK/QUALITY (R3) & LEVERAGING AI TO ACCELERATE TRIALS

14:35 Clinical Research News' Best of Show Award (Sponsored by ClinEco):

Recognising Exceptional Innovation in Technologies Used by Clinical Research Professionals

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News

The 2024 Best of Show Awards offer exhibitors of the SCOPE Summit Europe an exclusive opportunity to distinguish and highlight their products, ranging from an innovative application, technology, tool, or solution. The SCOPE community is invited to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year. Submit your entry! https://www.scopesummiteurope.com/sponsor-exhibitor/best-of-show-awards

14:40 FIRESIDE CHAT:

Redefining Excellence: The Future of Clinical Trial Quality

Coleen Glessner, Executive Vice President, Quality, Ethics and Compliance, Emergent BioSolutions

Kristi Koontz, Vice President, Global Clinical Operations, Daiichi Sankyo US

Patricia Leuchten, Founder & CEO, Diligent Pharma

Shyard Wong, Head, Clinical Quality & Continuous Improvement, Sanofi

This keynote explores milestones that have shaped our present approach to clinical trial quality; how standards for excellence are evolving; and what the future holds for clinical trial quality. Patty Leuchten, Founder and CEO of Diligent Pharma, will moderate a fireside chat with industry leaders: Coleen Glessner, Executive Vice President, Quality, Ethics, and Compliance from Emergent BioSolutions; and Shyard Wong, Global Head, Clinical Quality and Continuous Improvement from Sanofi.

15:05

PLENARY PRESENTATION: Use Case: From Theory to Therapy—Accelerating Clinical Trials with AI

Jonathan Crowther, PhD, Head Predictive Analytics, PRD (OARS), Pfizer Inc.

An exploration of the future potential of GenAI in clinical trials, focusing on optimising trial efficiency, reducing costs, and the broader business impact. Inspire the audience to think about the long-term benefits of integrating GenAI into their processes.

15:20 KEYNOTE PANEL DISCUSSION:

Data to Decisions: GenAI's Role in Transforming Clinical Trials

PANEL MODERATOR:

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News

Artificial intelligence, data analytics, automation, and technology have the power to connect stakeholders and applications and enhance protocol design, study feasibility, and patient identification and recruitment. The recent explosion of innovation with generative AI is delivering promising advances as we all know. However, this involves constructing a robust data infrastructure, harnessing cutting-edge technologies, adhering to privacy and data security regulations, and enforcing data governance principles.

PANELISTS:

Dorothee B. Bartels, PhD, Associate Professor (Apl. Professor) for Public Health and Epidemiology, Medizinische Hochschule Hannover; Founder, HealthData-Advisors, Board BBraun US

Jonathan Crowther, PhD, Head Predictive Analytics, PRD (OARS), Pfizer Inc.

Farrell Healion, Senior Director Emerging Technologies, Global Clinical Solutions, AstraZeneca

Close of Summit15:45